For babies born to hepatitis B carriers, the hepatitis B vaccine is required at birth, as well as hepatitis B immunoglobulin to block potential mother-to-child transmission. Hepatitis B is a chronic infectious disease that seriously threatens the health of our people. Hepatitis B virus infection can lead to hepatitis, liver fibrosis, liver cirrhosis and even liver cancer. For pregnant women with hepatitis B virus, if the hepatitis B virus DNA load is very high, reaching 10^6mIU/ml or more, in order to block mother-to-child transmission, it is recommended that pregnant women should undergo antiviral treatment at 24-28 weeks. The first-line antiviral treatment drug is tenofovir, which can effectively reduce the probability of mother-to-child transmission by reducing the viral load.